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Abstract
Preclinical studies suggest that insulin-like growth factor-I (IGF-I) plays an important role in
oligodendrocyte survival and myelination. We used human recombinant [125I]IGF-I to study
IGF-I receptors in post-mortem brain tissue from patients with multiple sclerosis (MS). In
normal appearing white matter, we found that IGF-I receptor densities and binding
characteristics were not different between MS patients and controls. In chronic plaques,
histologically characterised by astrogliosis, we found densities of IGF-I receptors, which were
in the same range as those measured in the normal appearing white matter. In vitro studies
have shown that IGF-I also acts as a mitogenic factor for astrocytes. Since MS lesions are
rapidly invaded by reactive astrocytes, IGF-I may not only protect oligodendrocytes and
stimulate remyelination but also enhance the astrogliosis that limits repair.
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Introduction
Insulin-like growth factor I (IGF-I) promotes the survival and regeneration of
oligodendrocytes in culture systems and stimulates the synthesis of myelin by regulating the
expression of myelin genes in oligodendrocytes 2,11,12. Transgenic mice, which overexpress
IGF-I, have an increased myelin content in their central nervous system 4, whereas
oligodendrocytes and myelin are deficient in mice homozygous for disrupted IGF-I gene 3.
We have previously shown that the central white matter in neonates, undergoing active
myelination, contains a 3-fold higher density of IGF-I receptors than in adults, suggesting that
also in human brain IGF-I and IGF-I receptors play an important role in the myelination
process 6. In the monophasic model of experimental allergic encephalomyelitis (EAE),
treatment with IGF-I reduces clinical deficits and lesion severity 9,16. Therefore, it has been
suggested that IGF-I may be useful as a treatment for multiple sclerosis  (MS). However,
information concerning IGF-I receptors in the central nervous system in MS is lacking. We




The experiments on post-mortem brains were approved by an Ethical Committee. Slices (±
0.5 cm thick) of frontal lobe were obtained from 4 patients with neuropathologically
confirmed MS (3 females and 1 male; mean age 69 ± 7 years; mean post-mortem delay 8 ±
1h) and 5 neurologically intact controls (3 females and 2 males; mean age 68 ± 9 years; mean
post-mortem delay 10 ± 2 h). The slices were quickly frozen in liquid nitrogen or with dry ice
and stored at –80°C. 
Radioligand bindingassays
Cryostat sections of 20-µm thickness were thaw-mounted on gelatine-coated microscopic
glass slides and dried overnight. The optimal incubation conditions were determined in
previous experiments 7. In brief, the slide-mounted sections were pre-incubated for 15 min at
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25°C in 25 mM Tris-HCl pH 7.5 containing 10 mM MgCl2 and 0.1% bovine serum albumin.
Consecutive sections were incubated in duplicate for 60 min at 25°C in the same buffer with
0.1 nM human recombinant [1 2 5I]IGF-I (Amersham, Buckinhhamshire, UK). After
incubation, the sections were washed 3 times for 1 min each in the same buffer to remove
unbound ligand and then quickly dipped in distilled water.
For competition binding experiments, the cerebral cortex was removed from the white matter.
The washed sections were wiped from the slides using glass fiber filters and radioactivity was
determined in a gamma-counter. Binding isotherms were analysed by non-linear least-square
curve fitting. The dissociation constants (Ki values) of the competitors IGF-I, DES(1–3 )IGF-I
and R3IGF-I (Gropep, Adelaide, Australia) were calculated from the corresponding IC50
values by the method of Cheng and Prusoff 
5
. DES(1–3)IGF-I and R3IGF-I are analogues of
IGF-I which display high affinity for IGF-I receptors but not for IGF-binding proteins 10. In
these experiments, non-specific binding of [125I]IGF-I was determined in the presence of 0.5
µM IGF-I.
For quantitative autoradiography, the sections were dried, placed in X-ray cassettes together
with commercially available [125I]standards (Amersham) and apposed to [3H] Ultrofilm
(Amersham) for 4 days. Non-specific binding of [125I]IGF-I was determined in consecutive
sections in the presence of 0.5 µM DES(1–3)IGF-I. The autoradiographic images obtained on
the films were scanned and analysed by computer-assisted densitometry using NIH Image
Analysis software Macintosh. Mean optical densities were determined and converted into
disintegration/min/mg protein and fmol/mg protein, based on the experimentally determined
relation between polymer and brain paste standards. Specific binding values were obtained by
the subtraction of non-specific binding from total binding.
Consecutive sections were also stained with luxol fast blue (myelin staining) and examined by
light microscopy to identify normal appearing white matter and demyelinated plaques. Glial
fibrillary acidic protein (GFAP) immunoperoxidase staining was used to identify astrocytes.
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Results
Binding studies and receptor concentrations
Representative competition binding experiments in central white matter are shown in Figure
1. Both DES(1–3)IGF-I and R3IGF-I displaced the same amount of [125I]IGF-I, indicating
that in the conditions used in our assays, [125I]IGF-I binds to IGF-I receptors and not to IGF-
binding proteins. Computer analysis of the binding data revealed that the competition curves
were best described by a one-component binding model.
The calculated Ki values for IGF-I, DES(1–3)IGF-I and R3IGF-I were similar between MS
patients and controls (Table 1). IGF-I receptor densities in normal appearing white matter and
cerebral cortex from MS patients were not different from those in controls (Table 2).
Seven demyelinated plaques were identified by luxol fast blue staining of the frozen sections.
Histologically all demyelinated lesions were identified as inactive chronic plaques, devoid of
an inflammatory response (absence of monocytic infiltrations) and characterised by extensive
astrogliosis. The astrocytes were identified by their morphology and GFAP immunoreactivity
(Figure 2). In all these plaques, we measured only slightly reduced densities of IGF-I
receptors (Table 2); the difference in receptor densities between normal appearing white
matter and plaques was not detectable on visual inspection of the autoradiopgraphs (Figure 3).
Table 1 [125I]IGF-I competition binding experiments in central white matter
Compound MS patients (n = 3) Controls (n = 3)
IGF-I 1.04 ± 0.18 0.90 ± 0.20
DES(1-3)IGF-I 0.95 ± 0.23 0,75 ± 0.07
R3IGF-I 0.77 ± 0.12 0.95 ± 0.22
Ki values (nM) of IGF-I, DES(1-3)IGF-I, and R3IGF-I for competition with [125I]IGF-I binding in
microtome sections of central white matter (from the frontal lobe) are given as the mean ± S.E.M.
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Table 2 IGF-I receptor densities in human frontal cortex and central white matter from
patients with MS and controls.
Cerebral cortex normal appearing plaques
 white matter               (n = 7)
Controls  (n = 5) 23.83 ± 1.54 11.81 ± 2.05 -
MS patients (n = 4)            23.07 ± 2.52 11.43 ± 2.03 8.66 ± 1.31
Receptor densities were obtained from [125I]IGF-I receptor autoradiographs and are expressed in
fmol/mg protein. Non-specific binding of [125I]IGF-I was determined in consecutive sections in the
presence of 0.5 µM DES(1-3)IGF-I. Values are means ± S.D.
Figure 1
Representative competition binding curves for IGF-I (), DES(1-
3)IGF-I () and R3IGF-I () inhibition of 0.1 nM [125I]IGF-I binding
on microtome sections of central white matter from a patient with MS.
Ki values are given in Table 1.
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Figure 2
Immunoperoxidase staining for glial fibrillary acidic protein (X250)
demonstrating the dense astrogliosis in one of the chronic plaques.
Figure 3
Consecutive microtome sections (20-µm thickness) from the frontal lobe of a patient with
MS. The left section shows the myelin staining with luxol fast blue discriminating a
plaque (the pale area) from normal appearing white matter (surrounding the pale area).
The right section shows an autoradiograph of the specific binding (= total minus non-
specific binding) of [125I]IGF-I receptors in white matter and cerebral cortex. Both the
normal appearing white matter and plaque contain a substantial amount of IGF-I
receptors. The dark rim on the right side of the section is the cerebral cortex, which
contains a much higher IGF-I receptor density.
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Discussion
MS is a chronic demyelinating disorder and is the most common cause of disability in the
young adult. The aetiology remains unknown. One hypothesis suggests that MS patients may
be relatively deficient in intrinsic mechanisms for limiting CNS tissue injury following
common insults, especially in the capacity for myelin repair 14. IGF-I and IGF-I receptors
appear to play a key role in the myelination process.
Our findings indicate that there is no deficiency in IGF-I receptors in MS brain and that
interventions for the promotion of remyelination in MS through IGF-I receptor activation
might be feasible. IGF-I can cross the blood–brain barrier in normal adult rats 13. In active
inflammatory demyelinating lesions, higher levels of IGF-I may be expected because there is
a disruption of the blood–brain barrier. Studies in the EAE model also suggest that the
systemic administration of IGF-I may have potential utility in the treatment of MS 9,16.
However, we found that IGF-I receptor densities in chronic MS plaques were only slightly
reduced and, on visual inspection of the autoradiographs, we were unable to distinguish
plaques from normal appearing white matter. Chronic plaques are devoid of oligodendrocytes
and contain a dense network of astrocytes responsible for the characteristic astrogliosis 14. In
vitro studies have shown that IGF-I is also a mitogenic compound for astrocytes 1,15. This may
have implications for the clinical use of IGF-I in MS. Acute MS lesions are rapidly invaded
by reactive astrocytes 14. Therefore, the administration of IGF-I to MS patients might not only
protect oligodendrocytes and stimulate remyelination but also enhance the astrogliosis that
limits repair. This may suggest that there exists a narrow therapeutic time window for IGF-I
to be beneficial in MS when administered in patients with a relapse, or it should be given
prophylactically in the early stages of the disease.
Additional research is needed before administering IGF-I to patients with MS. Valuable
information can be obtained by studying the effects of IGF-I in the chronic relapsing form of
EAE where substantial astrogliosis also occurs, just as it does in MS 8.
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